C4 Therapeutics (CCCC) Change in Receivables (2019 - 2026)

C4 Therapeutics' Change in Receivables history runs 8 years deep, the most recent figure standing at $482000.0 for Q1 2026.

• In Q1 2026, Change in Receivables fell 90.22% year-over-year to $482000.0; the TTM figure through Mar 2026 stood at -$5.1 million (up 7.63% YoY), while the FY2025 annual figure was -$701000.0, up 91.94% from the prior year.
• Change in Receivables was $482000.0 for Q1 2026 at C4 Therapeutics, up from -$4.1 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $11.3 million in Q4 2023 to a low of -$12.4 million in Q2 2024.
• Historically, Change in Receivables has averaged -$166647.1 across 5 years, with a median of -$63000.0 in 2022.
• The sharpest annual moves came in 2023 and 2024: Change in Receivables soared 75433.33% in 2023, then sank 2586.2% in 2024.
• A 5-year view of Change in Receivables shows it stood at -$15000.0 in 2022, then jumped by 75433.33% to $11.3 million in 2023, then plunged by 164.06% to -$7.2 million in 2024, then surged by 42.8% to -$4.1 million in 2025, then soared by 111.64% to $482000.0 in 2026.
• The last three Change in Receivables figures came in at $482000.0 (Q1 2026), -$4.1 million (Q4 2025), and $4.3 million (Q3 2025), per Business Quant data.